Drugs for a plethora of diseases like cancers, arthritis, HIV, diabetes, rare diseases are anticipated to make it big in …
You have read of your 8 free articles this month.
Subscribe to
Medgenera All-Access
Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.
Access articles & resources worth up to US $4, 000 per month.
Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing
Healthcare News You Won't Read Elsewhere
Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.
Access articles & resources worth up to $4000.
More in NEWLY PUBLISHED
NEWLY PUBLISHED
21 Leading Indian Cancer Startups
India is expected to have over 17.3 lakh new cases of cancer of which more than 8.8 lakh are likely ...
NEWLY PUBLISHED
40 World’s Top Selling Drugs by 2022
Drugs for a plethora of diseases like cancers, arthritis, HIV, diabetes, rare diseases are anticipated to make it big in ...
Artificial Intelligence
UPDATE: Indian Artificial Intelligence Startup Bags $19 Million for Healthcare Solutions
Bangalore-based Artificial Intelligence (AI) startup, SigTuple has raised $19 million (about INR 130 crore) in series B funding round led by Accel Partners and IDG Ventures. SigTuple funding.
DRUG TRIAL
FDA Approves First Therapy ‘Gilenya’ for Children with Multiple Sclerosis
Gilenya is the first FDA-approved drug for the treatment of multiple sclerosis (MS) in pediatric patients. Earlier it was approved in 2010 to treat adult patients with relapsing MS.
Most Popular
GROW
7 New Ideas to Start a Healthcare Business in India (2018)
Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?
NEWLY PUBLISHED
Pharma Patents: Can India Reward Incremental Innovation?
Leave a reply